Menu

Articles by : Shannon Young, Associate Editor/Senior Writer

Key U.S. Senate 340B Critic Faces Tough Reelection Bid in Louisiana’s Saturday GOP Primary

Shannon Young, Associate Editor/Senior Writer 340B Report Views
Letlow, Cassidy and Fleming headshots
U.S. Sen. Bill Cassidy (center) will face U.S. Rep. Julia Letlow (left) and Louisiana State Treasurer John Fleming (right) in Louisiana’s May 16 GOP U.S. Senate primary election. (Photos courtesy: Congressional websites, Louisiana State Treasurer's website)
A high-ranking U.S. senator, who’s been a chief critic of the 340B program, will square off Saturday against two GOP [...]

Please Login or Become a Paid Subscriber to View this Content

…
Read More »

UCB 7th to Announce In-House Pharmacy Claims Data Requirements, AbbVie Updates States Subject to CP Restrictions

Shannon Young, Associate Editor/Senior Writer 340B Report Views
UCB building exterior
UCB became the seventh manufacturer to announce an expansion of its 340B claims data requirements to in-house pharmacy use.

A Brussels-based drugmaker recently became the seventh manufacturer to announce an expansion of its 340B claims data requirements to in-house pharmacy use, while a Chicago-based pharmaceutical giant updated its contract pharmacy restrictions to exempt Washington state covered entities.

UCB informed

…
Read More »

COA Board Member Calls for 340B Reform, Cassidy Largely Quiet on Program at Senate HELP Field Hearing

Shannon Young, Associate Editor/Senior Writer 340B Report Views
Screenshot of HELP Committee hearing in Baton Rouge, La.
U.S. Sen. Bill Cassidy (R-La.) led a May 5 HELP Committee hearing in Baton Rouge, at which one witness called for 340B reform.
A Louisiana cancer center leader—who serves on the board of a private practice oncologist trade group that’s corporate partners largely [...]

Please Login or Become a Paid Subscriber to View this Content

…
Read More »

PhRMA Again Targets 340B ‘Markups’ in New Seven-Figure Ad Campaign 

Shannon Young, Associate Editor/Senior Writer 340B Report Views
Screenshot of PhRMA Goldmine spa ad
PhRMA released a 30-second video ad Wednesday arguing that “340B medicine markups are a goldmine for big hospital systems.”
Washington D.C.’s most powerful drug industry trade group launched a new ad Wednesday accusing 340B hospitals of profiting off “medicine [...]

Please Login or Become a Paid Subscriber to View this Content

…
Read More »

Amphastar Pharmaceuticals 42nd Drugmaker to Place 340B Contract Pharmacy Restrictions, 5th to Use Truzo

Shannon Young, Associate Editor/Senior Writer 340B Report Views
Amphastar logo
Amphastar Pharmaceuticals is the 42nd drugmaker to announce 340B contract pharmacy restrictions and the fifth to utilize Truzo.
A California-based drugmaker this week announced new contract pharmacy restrictions for covered entities looking to purchase a low blood sugar [...]

Please Login or Become a Paid Subscriber to View this Content

…
Read More »

Biogen Becomes 6th Drugmaker to Announce In-House Pharmacy Claims Data Requirements

Shannon Young, Associate Editor/Senior Writer 340B Report Views
Biogen HQ exterior
Biogen recently announced it's expanding its 340B claims data requirements to in-house pharmacy use, making it the sixth drugmaker to do so.
A Massachusetts pharmaceutical manufacturer recently announced plans to expand its 340B claims data requirements to in-house pharmacy use, making it [...]

Please Login or Become a Paid Subscriber to View this Content

…
Read More »

Gilead Latest Drugmaker to Move to Truzo, Kalderos’ Platform for 340B Contract Pharmacy Restrictions

Shannon Young, Associate Editor/Senior Writer 340B Report Views
Gilead logo
Gilead announced it will move its 340B contract pharmacy claims review and policy oversight duties from Second Sight Solutions’ 340B ESP to Kalderos’ Truzo as of June 15.
A California-based drugmaker recently announced that it will become the fourth drugmaker to utilize a new platform for its 340B [...]

Please Login or Become a Paid Subscriber to View this Content

…
Read More »

Stemline Therapeutics 41st Drugmaker to Enact 340B Contract Pharmacy Restrictions

Shannon Young, Associate Editor/Senior Writer 340B Report Views
Stemline logo.
Stemline Therapeutics announced its contract pharmacy restrictions for Orserdu will take effect May 18.
A New York-based drugmaker recently announced new contract pharmacy restrictions for covered entities looking to purchase a breast cancer treatment [...]

Please Login or Become a Paid Subscriber to View this Content

…
Read More »

Three Drugmakers to Refund 340B Covered Entities for Overcharges, One Announces NDC Changes

Shannon Young, Associate Editor/Senior Writer 340B Report Views
A screenshot of HRSA website
Three drugmakers recently announced refunds to 340B covered entities for overcharges, while one announced NDC changes.
Three drugmakers recently announced refunds to 340B covered entities that purchased certain medications between 2024 and 2026, while a New [...]

Please Login or Become a Paid Subscriber to View this Content

…
Read More »

News Alert

UPDATED: GOP Lawmakers Accuse Urban Hospitals of Misusing 340B Program at U.S. House Hearing

Shannon Young, Associate Editor/Senior Writer 340B Report Views
U.S. Rep. Jason Smith (R-Mo.) began the House Ways & Means Committee’s hearing by arguing that large hospital systems “manipulate the 340B drug pricing program to keep steep drug discounts for themselves instead of passing the savings to low-income patients.”
Republican members of a key U.S. House panel on Tuesday criticized some 340B urban hospitals’ use of a rural designation—accusing [...]

Please Login or Become a Paid Subscriber to View this Content

…
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Site Footer Live

; ?>